Loading cart

Priority-driven Collaborative Cancer Research Scheme

Cancer Australia has developed the Priority-driven Collaborative Cancer Research Scheme to support research that reduces the impact of cancer on the community and improves outcomes for people affected by cancer.

Overview

The Priority-driven Collaborative Cancer Research Scheme is an innovative annual national research project grants funding scheme which brings together government and other funders of cancer research to collaboratively fund cancer research in Australia.

This funding scheme helps to:

  • coordinate funding of priority-driven cancer research at the national level,
  • foster collaboration between cancer researchers to build Australia’s cancer research capacity, and
  • foster consumer participation in cancer research, from design to implementation.

Working with the National Health and Medical Research Council (NHMRC)

This research scheme is managed by Cancer Australia and the agency collaborates with the NHMRC in this grant scheme. The NHMRC facilitates registration and initial assessment of applications, and endorses grants funded through this scheme in recognition of their scientific merit.

Successful applicants for 2016 Round

On 12 December 2016, the Australian Government announced successful applicants for the 2016 round of the Priority-driven Collaborative Cancer Research Scheme, proudly funded by Cancer Australia, the Australasian Sarcoma Study Group, Cancer Council Australia, Cancer Council NSW, Cure Cancer Australia, National Breast Cancer Foundation and The Kids’ Cancer Project.

The successful grants in the 2016 round of the PdCCRS are as follows:

Agar, Meera
University of Technology Sydney
Randomised double blind placebo controlled phase III trial of oral melatonin for the prevention of delirium in hospitalised advanced cancer patients
Funded by Cancer Australia

Batra, Jyotsna
Queensland University of Technology
Functional and mechanistic characterisation of a novel LncRNA at chromosomal locus 5p15 in prostate cancer
Funded by Cure Cancer Australia

Cao, Yuan
Peter MacCallum Cancer Centre
Targeting matrix metalloproteinase-12 (MMP12) promotes an immune response against breast cancer
Funded by Cure Cancer Australia

Carter, Daniel
Children's Cancer Institute
Targeting FACT to inhibit MYCN-driven transcription in neuroblastoma
Co-funded by Cancer Australia and The Kids’ Cancer Project

Castano-Rodriguez, Natalia
University of NSW
The role of autophagy in gastric carcinogenesis
Funded by Cure Cancer Australia

Cook, Matthew
Australian National University
AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors
Funded by Cancer Australia

Deans, Andrew
St Vincent’s Institute of Medical Research
Are FANCC and FANCM breast cancer predisposition genes?
Funded by the National Breast Cancer Foundation

D'Souza, Rochelle
QIMR Berghofer Medical Research Institute
Understanding the tumour suppressive function of ephrin A5 signalling in adult brain cancer
Funded by Cure Cancer Australia

Gould, Gillian
University of Newcastle
Assessing Behaviour Change Techniques for Indigenous Pregnant Smokers attending Aboriginal Medical Services - a nested study in a cluster Randomised Controlled Trial
Co-funded by Cancer Australia and Cure Cancer Australia

Guillerey, Camille
QIMR Berghofer Medical Research Institute
Improving Natural Killer cell responses to immunotherapy in haematological cancers
Co-funded by Cancer Australia and Cure Cancer Australia

Hovey, Elizabeth
Prince of Wales Hospital
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma: the CODEL trial
Co-funded by Cancer Australia and Cancer Council NSW

Lane, Steven
QIMR Berghofer Medical Research Institute
Dnmt3a loss contributes to disease progression in myeloproliferative neoplasm
Co-funded by Cancer Australia and Cure Cancer Australia

Lee, Gary
University of WA
FGF-Receptor Antagonist in Mesothelioma (FRAME) Study: A Phase II Clinical Trial
Funded by Cancer Australia

Lim, Su Yin
Macquarie University
Differential effects of MAPK inhibition on immune activity determine melanoma response
Co-funded by Cancer Australia and Cure Cancer Australia

Lock, Richard
Children's Cancer Institute
Reversing glucocorticoid resistance in paediatric acute lymphoblastic leukaemia - a novel epigenetic mechanism linked to lymphocyte-specific chromatin conformation
Co-funded by Cancer Australia and The Kids’ Cancer Project

Mielke, Lisa
Walter & Eliza Hall Institute of Medical Research
Transcriptional control of IL-17 producing T cells in gastrointestinal cancers.
Co-funded by Cancer Australia and Cure Cancer Australia

Morton, Rachel
University of Sydney
Computed tomography (CT) and positron emission tomography (PET)/CT surveillance imaging in asymptomatic Stage III melanoma patients - a prospective cohort study of clinical benefit and economic implications
Funded by Cancer Australia

Naylor, Matthew
University of Sydney
Targeting ACC1 as a novel therapeutic for the treatment of breast cancer
Funded by the National Breast Cancer Foundation

O'Brien, Ricky
University of Sydney
High Precision Radiotherapy: Dual Cardiac and Respiratory Motion Management
Funded by Cancer Australia

Phillips, Phoebe
University of NSW
Reprogramming the Tumour Microenvironment with the use of Nanomedicines for the Treatment of Pancreatic Cancer
Co-funded by Cancer Australia and Cancer Council Australia

Sahni, Sumit
University of Sydney
Molecular Role of the AMPK-Dependent Pathway in the Activity of Thiosemicarbazones Against Pancreatic Cancer.
Funded by Cure Cancer Australia

Segelov, Eva
University of NSW
ASCOLT: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Trial
Co-funded by Cancer Australia and Cancer Council NSW

Sharbeen, George
Lowy Cancer Research Centre
MutY-Homolog is a Potential Therapeutic Target for Pancreatic Cancer
Funded by Cure Cancer Australia

Sieber, Oliver
The Walter and Eliza Hall Institute of Medical Research
Development of a Clinico-Molecular Colon Cancer Nomogram for personalisation of adjuvant chemotherapy in the Australian population
Funded by Cancer Australia

Sjoquist, Katrin
NHMRC Clinical Trials Centre
Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations
Co-funded by Cancer Australia and the National Breast Cancer Foundation

Souza-Fonseca-Guimaraes, Fernando
Walter & Eliza Hall Institute of Medical Research
Targeting suppressive TGF-beta to enhance innate lymphoid cell response against melanoma
Funded by Cure Cancer Australia

Taylor, Natalie
Macquarie University
Hide and seek with hereditary cancer: Improving detection of colorectal cancer patients with a high risk of Lynch syndrome
Funded by Cancer Australia

Thomas, David
Garvan Institute of Medical Research
A surveillance protocol for people at high risk of cancer using whole body magnetic resonance
Funded by the Australasian Sarcoma Study Group

Ziegler, David
Sydney Children's Hospital
Synthetic retinoid therapy for Diffuse Intrinsic Pontine Gliomas
Co-funded by Cancer Australia, Cancer Council NSW and The Kids’ Cancer Project


Cancer Australia's funding partners and successful applicants in previous PdCCRS rounds

2015

2014

2013

2012

2011

  • Successful applicants for 2011 round (PDF 268KB)

2010

2009

2008

2007

Find out more about: